Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$44.62

0.18 (0.41%)

04:55
08/21/19
08/21
04:55
08/21/19
04:55

AstraZeneca management to meet with Jefferies

Meeting to be held in San Francisco on August 21 hosted by Jefferies.

  • 21

    Aug

  • 06

    Sep

  • 09

    Sep

  • 16

    Sep

  • 25

    Sep

  • 02

    Oct

AZN AstraZeneca
$44.62

0.18 (0.41%)

07/26/19
HCWC
07/26/19
NO CHANGE
HCWC
Amarin prepared to defend patents against Epanova launch, says H.C. Wainwright
After speaking with an intellectual property attorney, H.C. Wainwright analyst Andrew Fein believes Amarin (AMRN) has prepared itself to defend its patents for Vascepa against a possible launch of AstraZeneca's (AZN) omega-3 Epanova. The consultation revealed the FDA's Orange Book includes 25 patents listed for Vascepa, Fein tells investors in a research note. While, according to the IP attorney, Amarin's Orange Book patents do not appear to directly address Epanova, Amarin has a large patent portfolio in this space, says the analyst. Fein points out that Amarin could not hypothetically sue AstraZeneca for patent infringement until Epanova was made, used, or sold in a commercial context. These are not brand-generic circumstances between both companies, he writes. However, Fein thinks Amarin's patents could give it the upper hand and he reiterates a Buy rating on the shares with a $51 price target.
07/29/19
WBLR
07/29/19
NO CHANGE
WBLR
Outperform
Updates 'very positive' for upcoming Pieris presentation, says William Blair
Pieris Pharmaceuticals (PIRS) will present Phase Ib safety and efficacy results with PRS-060, an inhaled IL-4R alpha inhibitor, at the upcoming European Respiratory Society International Congress, held September 28 through October 2, William Blair analyst Matt Phipps tells investors in a research note. The poster presentation to be presented on October 1 is titled, "Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," the analyst point out. In addition, AstraZeneca (AZN) plans to initiate a Phase II trial with AZD1402/PRS-060 in the second half of this year, according to its recent earnings presentation, adds Phipps. He views these updates as "very positive" for the upcoming presentation, and believes PRS-060 has "significant potential" in the treatment of asthma patients. Phipps keeps an Outperform rating on Pieris Pharmaceuticals.
08/13/19
BOFA
08/13/19
DOWNGRADE
Target $7
BOFA
Neutral
Clovis downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill Tazeen Ahmad downgraded Clovis (CLVS) to Neutral and lowered his price target to $7 from $13 after last week's release of positive topline results for its PARP inhibitor Lynparza to treat prostate cancer by the company's competitor AstraZeneca (AZN). The analyst notes that the Lynparza update alters his expectations in the prostate cancer market to assume a two-player landscape from day one, reducing his expectations for Clovis's Rubraca peak sales to $250M from $406M with peak U.S. BRCA penetration of 15%.
08/14/19
ARGS
08/14/19
NO CHANGE
Target $50
ARGS
Buy
AstraZeneca price target raised to $50 from $46 at Argus
Argus analyst John Eade raised his price target on AstraZeneca to $50 and kept his Buy rating, saying the stock has outperformed over the past quarter thanks to the pipeline developments that are returning the company to growth. The analyst notes that the company's future growth should be driven by its checkpoint inhibitor Imfinzi, and he sees the program tracking toward a billion-dollar blockbuster status from $338M reported in Q2. Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.

TODAY'S FREE FLY STORIES

ABT

Abbott

$84.25

-0.96 (-1.13%)

, ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

13:22
09/14/19
09/14
13:22
09/14/19
13:22
Conference/Events
William Blair diagnostic products/med tech analyst to hold a group luncheon »

Diagnostic Products &…

ABT

Abbott

$84.25

-0.96 (-1.13%)

ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

BDX

Becton Dickinson

$260.68

-1.41 (-0.54%)

COO

Cooper Companies

$301.95

-3 (-0.98%)

EXAS

Exact Sciences

$106.72

-1.99 (-1.83%)

GH

Guardant Health

$77.54

0.49 (0.64%)

NEO

NeoGenomics

$21.34

-1.22 (-5.41%)

LMNX

Luminex

$22.62

0.1 (0.44%)

HAE

Haemonetics

$125.55

-0.31 (-0.25%)

STAA

STAAR Surgical

$29.21

0.415 (1.44%)

QGEN

Qiagen

$33.97

-0.105 (-0.31%)

NVTA

Invitae

$21.70

-0.2 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 13

    Nov

  • 05

    Dec

CRTO

Criteo

, TWTR

Twitter

13:19
09/14/19
09/14
13:19
09/14/19
13:19
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

Technology & Internet…

CRTO

Criteo

TWTR

Twitter

SNAP

Snap

GOOGL

Alphabet Class A

FB

Facebook

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

T

AT&T

$37.90

-0.46 (-1.20%)

09:06
09/14/19
09/14
09:06
09/14/19
09:06
Periodicals
AT&T stock already benefiting from activist involvement, Barron's says »

AT&T 's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

DIS

Disney

$138.00

0.44 (0.32%)

, NFLX

Netflix

$294.00

5.08 (1.76%)

09:04
09/14/19
09/14
09:04
09/14/19
09:04
Periodicals
Consumers might not be as in love with Apple TV+ as Wall Street, Barron's says »

Following Apple's…

DIS

Disney

$138.00

0.44 (0.32%)

NFLX

Netflix

$294.00

5.08 (1.76%)

AAPL

Apple

$218.71

-4.4 (-1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Oct

UAL

United Airlines

$91.37

1.99 (2.23%)

08:58
09/14/19
09/14
08:58
09/14/19
08:58
Periodicals
United Airlines could get boost after short squeeze, Barron's says »

United Airlines stock has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BAC

Bank of America

$30.12

0.44 (1.48%)

08:55
09/14/19
09/14
08:55
09/14/19
08:55
Periodicals
Bank of America stock worth betting on, Barron's says »

Amid talk of a coming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TPR

Tapestry

$25.16

-0.43 (-1.68%)

08:49
09/14/19
09/14
08:49
09/14/19
08:49
Periodicals
Coach parent's turnaround could be coming, Barron's says »

Even in a rough year for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$379.63

4.21 (1.12%)

08:45
09/14/19
09/14
08:45
09/14/19
08:45
Periodicals
U-Haul parent stock 'a better-kept secret,' Barron's says »

Amerco (UHAL), owner of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

, CNI

Canadian National

$92.13

-0.31 (-0.34%)

08:41
09/14/19
09/14
08:41
09/14/19
08:41
Periodicals
Railroad stocks struggling as challenges increase, Barron's says »

North American railroads…

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

CNI

Canadian National

$92.13

-0.31 (-0.34%)

UNP

Union Pacific

$171.49

3.81 (2.27%)

CSX

CSX

$72.50

0.96 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

MO

Altria Group

$42.01

-0.77 (-1.80%)

, BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

08:06
09/14/19
09/14
08:06
09/14/19
08:06
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

MO

Altria Group

$42.01

-0.77 (-1.80%)

BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$73.01

-1.89 (-2.52%)

REGI

Renewable Energy

$15.90

0.57 (3.72%)

PSX

Phillips 66

$102.77

0.66 (0.65%)

MPC

Marathon Petroleum

$53.29

0.1 (0.19%)

VLO

Valero

$85.53

1.84 (2.20%)

EVA

Enviva

$31.21

0.06 (0.19%)

AMTX

Aemetis

$1.00

0.14 (16.28%)

PEIX

Pacific Ethanol

$0.78

0.0322 (4.29%)

GPP

Green Plains Partners

$13.18

0.17 (1.31%)

DK

Delek US

$35.91

-0.6 (-1.64%)

HFC

HollyFrontier

$51.41

0.71 (1.40%)

TSO

Tesoro

$0.00

(0.00%)

WNR

Western Refining

$0.00

(0.00%)

T

AT&T

$37.90

-0.46 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 23

    Oct

  • 24

    Oct

  • 31

    Oct

  • 12

    Nov

GLD

SPDR Gold Shares

$140.19

-1.14 (-0.81%)

17:58
09/13/19
09/13
17:58
09/13/19
17:58
Hot Stocks
SPDR Gold Shares holdings fall to 874.51MT from 880.37MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

, AIMT

Aimmune

$24.66

(0.00%)

17:57
09/13/19
09/13
17:57
09/13/19
17:57
Hot Stocks
Breaking Hot Stocks news story on DBV Technologies, Aimmune »

DBV Technologies falls 2%…

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

AIMT

Aimmune

$24.66

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

AIMT

Aimmune

$24.66

(0.00%)

17:55
09/13/19
09/13
17:55
09/13/19
17:55
Hot Stocks
FDA committee votes to support use of Aimmune's Palforzia for peanut allergy »

Aimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

ZAYO

Zayo Group

$33.82

-0.05 (-0.15%)

17:39
09/13/19
09/13
17:39
09/13/19
17:39
Hot Stocks
Zayo Group CEO sells 1M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

T

AT&T

$37.90

-0.46 (-1.20%)

, MO

Altria Group

$42.01

-0.77 (-1.80%)

17:38
09/13/19
09/13
17:38
09/13/19
17:38
Periodicals
CNN to longer run Juul ads, Daily Beast reports »

AT&T's (T) CNN…

T

AT&T

$37.90

-0.46 (-1.20%)

MO

Altria Group

$42.01

-0.77 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BAS

Basic Energy

$1.87

-0.08 (-4.10%)

17:34
09/13/19
09/13
17:34
09/13/19
17:34
Hot Stocks
Basic Energy CEO T.M. Patterson to leave company »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

XBIO

Xenetic

$1.61

-0.04 (-2.42%)

17:28
09/13/19
09/13
17:28
09/13/19
17:28
Syndicate
Breaking Syndicate news story on Xenetic »

Xenetic files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$218.71

-4.4 (-1.97%)

, DIS

Disney

$138.00

0.44 (0.32%)

17:22
09/13/19
09/13
17:22
09/13/19
17:22
Hot Stocks
Disney CEO Bob Iger resigns from Apple board of directors »

In a regulatory filing,…

AAPL

Apple

$218.71

-4.4 (-1.97%)

DIS

Disney

$138.00

0.44 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PHG

Philips

$47.79

0.19 (0.40%)

17:21
09/13/19
09/13
17:21
09/13/19
17:21
Hot Stocks
Philips awarded maximum $400M Defense Logistics Agency contract »

Philips has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBSE

NeuBase Therapeutics

$5.70

-0.04 (-0.70%)

17:20
09/13/19
09/13
17:20
09/13/19
17:20
Syndicate
Breaking Syndicate news story on NeuBase Therapeutics »

NeuBase Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$198.82

1.22 (0.62%)

17:17
09/13/19
09/13
17:17
09/13/19
17:17
Hot Stocks
Raytheon awarded $427.3M Army procurement contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

INPX

Inpixon

$0.14

-0.0001 (-0.07%)

17:16
09/13/19
09/13
17:16
09/13/19
17:16
Syndicate
Breaking Syndicate news story on Inpixon »

Inpixon files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$6.59

0.14 (2.17%)

17:14
09/13/19
09/13
17:14
09/13/19
17:14
Syndicate
Aurinia Pharmaceuticals files to sell $40M of common shares at-the-market »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.